Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 12/20 | 0.49 |
| ▸ | MPC2 | O95563 | 2/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12521788 | 0.89 | CYP3A4 (0.75) | CYP3A4MAPTMEN1ALDH1A1TP53 | |
| SCHEMBL11088249 | 0.87 | CYP3A4 (0.79) | CYP3A4MAPTMEN1ALDH1A1TP53 | |
| Ciglitazone SCHEMBL38185 | 0.87 | HPGD (1.00) | CYP3A4MAPTMEN1ALDH1A1TP53 | |
| Ciglitazone SCHEMBL20125581 | 0.87 | HPGD (1.00) | CYP3A4MAPTMEN1ALDH1A1TP53 | |
| Ciglitazone SCHEMBL20125576 | 0.87 | HPGD (1.00) | CYP3A4MAPTMEN1ALDH1A1TP53 | |
| Ciglitazone SCHEMBL21582134 | 0.86 | HPGD (0.98) | CYP3A4MAPTMEN1ALDH1A1TP53 | |
| Ciglitazone SCHEMBL3189397 | 0.86 | HPGD (0.98) | CYP3A4MAPTMEN1ALDH1A1TP53 | |
| SCHEMBL12521810 | 0.86 | CYP3A4 (0.61) | CYP3A4MAPTMEN1ALDH1A1TP53 | |
| SCHEMBL2786303 | 0.85 | HPGD (0.55) | CYP3A4MAPTMEN1ALDH1A1TP53 | |
| Ciglitazone SCHEMBL8498957 | 0.82 | HPGD (0.89) | CYP3A4MAPTMEN1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421197-B2 | Methods of generating hyper INOS expressing cells and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-08-23 | — | — | US | claimed |
| US-20140364461-A1 | METHOD OF TREATING DERMATOLOGICAL DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2014-12-11 | — | — | US | claimed |
| US-20140335105-A1 | METHODS OF GENERATING HYPER INOS EXPRESSING CELLS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-13 | — | — | US | claimed |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2014-08-21 | — | — | US | claimed |
| EP-2766018-A2 | RXR AGONISTS COMPOUNDS AND METHODS | Case Western Reserve University (US) | 2014-08-20 | — | — | EP | claimed |
| US-8796282-B2 | Method of treating dermatological disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-08-05 | — | — | US | claimed |
| US-8790925-B2 | Methods of generating hyper iNOS expressing cells and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-29 | — | — | US | claimed |
| US-20140170165-A1 | METHODS OF GENERATING HYPER INOS EXPRESSING CELLS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-06-19 | — | — | US | claimed |
| WO-2013056232-A2 | RXR AGONISTS COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-04-18 | — | — | WO | claimed |
| EP-2451455-A2 | RXR AGONIST COMPOUNDS AND METHODS | Case Western Reserve University (US) | 2012-05-16 | — | — | EP | claimed |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | LANDRETH GARY E (US) | 2012-05-10 | — | — | US | claimed |
| WO-2011100685-A2 | METHODS OF GENERATING HYPER INOS EXPRESSING CELLS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-08-18 | — | — | WO | claimed |
| WO-2011006157-A2 | RXR AGONIST COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-01-13 | — | — | WO | claimed |
| US-20100331330-A1 | METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC STROKE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-30 | — | — | US | claimed |
| US-20100022600-A1 | METHODS AND COMPOSITIONS FOR TREATING CENTRAL NERVOUS SYSTEM TUMORS | LANDRETH GARY E | 2010-01-28 | — | — | US | claimed |
| US-20090118337-A1 | Methods and compositions for treating inflammation | CASE WESTERN RESERVE UNIVERSITY | 2009-05-07 | — | — | US | claimed |
| US-20090042909-A1 | METHOD OF TREATING DERMATOLOGICAL DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2009-02-12 | — | — | US | claimed |
| WO-2008070230-A2 | METHODS AND COMPOSITIONS FOR TREATING CENTRAL NERVOS SYSTEM TUMORS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-06-12 | — | — | WO | claimed |
| WO-2008024749-A2 | METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC STROKE | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-02-28 | — | — | WO | claimed |
| US-9421197-B2 | Methods of generating hyper INOS expressing cells and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20140364461-A1 | METHOD OF TREATING DERMATOLOGICAL DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140335105-A1 | METHODS OF GENERATING HYPER INOS EXPRESSING CELLS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-13 | — | — | US | disclosed |
| US-8796282-B2 | Method of treating dermatological disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-08-05 | — | — | US | disclosed |
| US-8790925-B2 | Methods of generating hyper iNOS expressing cells and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20140170165-A1 | METHODS OF GENERATING HYPER INOS EXPRESSING CELLS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2451455-A2 | RXR AGONIST COMPOUNDS AND METHODS | Case Western Reserve University (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | LANDRETH GARY E (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2011091033-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011006157-A2 | RXR AGONIST COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100331330-A1 | METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC STROKE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-30 | — | — | US | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100022600-A1 | METHODS AND COMPOSITIONS FOR TREATING CENTRAL NERVOUS SYSTEM TUMORS | LANDRETH GARY E | 2010-01-28 | — | — | US | disclosed |
| US-20090118337-A1 | Methods and compositions for treating inflammation | CASE WESTERN RESERVE UNIVERSITY | 2009-05-07 | — | — | US | disclosed |
| US-20090042909-A1 | METHOD OF TREATING DERMATOLOGICAL DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2009-02-12 | — | — | US | disclosed |
| WO-2008070230-A2 | METHODS AND COMPOSITIONS FOR TREATING CENTRAL NERVOS SYSTEM TUMORS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008024749-A2 | METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC STROKE | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2006132928-A2 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2006-12-14 | — | — | WO | disclosed |
| US-6579893-B1 | Related thiazolidinediones | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-06-17 | — | — | US | disclosed |
| US-6579893-B1 | Related thiazolidinediones | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364461-A1 | METHOD OF TREATING DERMATOLOGICAL DISORDERS | PPARA, PPARG, PPARD | CYP3A4 1555/4885MAPT 2155/4885MEN1 4595/4885 |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | PPARG, PPARA, PPARD | CYP3A4 4831/4885MAPT 1770/4885MEN1 4688/4885 |
| US-20100331330-A1 | METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC STROKE | PPARG, PPARA, FABP7 | CYP3A4 3643/4885MAPT 1654/4885MEN1 4866/4885 |
| US-20090042909-A1 | METHOD OF TREATING DERMATOLOGICAL DISORDERS | PPARA, PPARG, PPARD | CYP3A4 1555/4885MAPT 2155/4885MEN1 4595/4885 |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | CYP3A4 1058/4885MAPT 1395/4885MEN1 4760/4885 |
| US-20090118337-A1 | Methods and compositions for treating inflammation | PPARG, PPARA, PPARD | CYP3A4 1874/4885MAPT 4665/4885MEN1 4883/4885 |
| US-20100022600-A1 | METHODS AND COMPOSITIONS FOR TREATING CENTRAL NERVOUS SYSTEM TUMORS | PPARG, PPARA, FABP7 | CYP3A4 2532/4885MAPT 2283/4885MEN1 1518/4885 |
| US-20120115912-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | CYP3A4 568/4885MAPT 3596/4885MEN1 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.